| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | RO-3306 | GDSC1000 | pan-cancer | AAC | 0.064 | 0.06 |
| mRNA | HG-6-64-1 | GDSC1000 | pan-cancer | AAC | 0.062 | 0.06 |
| mRNA | BRD1835 | CTRPv2 | pan-cancer | AAC | 0.07 | 0.07 |
| mRNA | XMD13-2 | GDSC1000 | pan-cancer | AAC | 0.057 | 0.07 |
| mRNA | WAY-362450 | CTRPv2 | pan-cancer | AAC | -0.069 | 0.07 |
| mRNA | EHT 1864 | GDSC1000 | pan-cancer | AAC | 0.062 | 0.07 |
| mRNA | 681640 | GDSC1000 | pan-cancer | AAC | 0.068 | 0.07 |
| mRNA | Crizotinib | CTRPv2 | pan-cancer | AAC | 0.059 | 0.07 |
| mRNA | Cytarabine | CTRPv2 | pan-cancer | AAC | 0.052 | 0.07 |
| mRNA | BRD4132 | CTRPv2 | pan-cancer | AAC | 0.069 | 0.07 |